Magnesium Acetate
CAS 142-72-3
Magnesium Acetate (CAS 142-72-3) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 4 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| MAGNESIUM ACETATE | 314718 | SU | MTHSPL |
| magnesium acetate | 314718 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Magnesium Acetate used for in pharmaceutical contexts?
Magnesium Acetate (CAS 142-72-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Magnesium Acetate?
Magnesium Acetate has 4 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain upper, Condition aggravated, Dizziness, Fatigue. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Magnesium Acetate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Magnesium Acetate with EU status "permitted".
What clinical phase is Magnesium Acetate in?
Magnesium Acetate is rendered with ChEMBL max phase 4 (approved).